Below are the financial statements of Aurobindo Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in billions of INR | 2023 |
|---|---|
| Revenue from operations | 84.57a |
| Other income | 4.44a |
| Total income | 89.01a |
| Expenses | — |
| Cost of materials consumed | -46.67a |
| Purchases of stock-in-trade | -0.89a |
| Changes in inventories of finished goods and work-in-progress | -2.64a |
| Employee benefits expense | -8.91a |
| Finance costs | -0.75a |
| Depreciation and amortisation expense | -2.43a |
| Other expenses | -15.7a |
| Total expenses | -72.7a |
| Profit before tax | 16.31a |
| Tax expenses | — |
| Current tax | -4.12a |
| Deferred tax | -0.23a |
| Total tax expense | -3.89a |
| Profit for the year | 12.42a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Aurobindo Pharma’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.